Clairity Breast becomes the first FDA-authorized AI software to predict five-year breast cancer risk using routine mammography images.
Key Details
- 1FDA grants de novo authorization to Clairity Breast, developed by Boston-based Clairity.
- 2The AI tool analyzes mammogram images for subtle features correlated with future cancer risk.
- 3Unlike traditional models, Clairity Breast does not require age or genetic data.
- 4The system was trained on millions of mammogram images linked to five-year outcomes.
- 5Clairity Breast delivers validated risk scores to radiologists through standard clinical systems.
- 6Commercial launch is targeted for the end of 2025.
Why It Matters
This breakthrough FDA authorization marks a new era in preventive oncology by enabling earlier risk identification using only imaging, potentially improving precision prevention and patient outcomes in breast cancer care.
Source
Radiology Business
Related News
•AuntMinnie
AI Model Using Mammograms Enhances Five-Year Breast Cancer Risk Assessment
A new image-only AI model more accurately predicts five-year breast cancer risk than breast density alone, according to multinational research presented at RSNA 2025.
•AuntMinnie
AI Advances Push Opportunistic Imaging Into Clinical Focus
AI-powered opportunistic screening is transforming routine radiological images into proactive tools for risk detection of major diseases.
•AuntMinnie
AI Workflow Boosts Breast Cancer Detection and Equity
Deployment of an AI-driven breast cancer screening workflow improved detection rates while maintaining equity across racial and breast density subgroups.